Migraine is a neurological condition — not just a bad headache. Understanding its mechanisms is the starting point for treatment that actually reduces frequency and severity.
Off-Label
rTMS for migraine is an off-label and investigational application in Australia. Medicare rebates under MBS 14216 and MBS 14217 apply for treatment-resistant depression only. rTMS for migraine is not Medicare-funded. All care is AHPRA-compliant and delivered under psychiatrist oversight with full informed consent.
Understanding the condition
What is migraine?
Migraine is a recurrent neurological condition characterised by moderate to severe headache — typically unilateral, pulsating, and aggravated by routine physical activity — accompanied by nausea, vomiting, or sensitivity to light and sound. Episodes typically last 4 to 72 hours. In some individuals, headache is preceded by aura: reversible neurological symptoms including visual disturbances, sensory changes, or speech difficulties.
Migraine is not a stress response or a tension headache. It involves changes in brain signalling, trigeminovascular activation, and cortical spreading depression — processes that are distinct, well-characterised neurobiologically, and that explain why migraine-specific treatments work differently from standard analgesics.
Chronic migraine is defined as 15 or more headache days per month, of which at least 8 meet migraine criteria. For patients at this frequency, the condition significantly disrupts work, relationships, and quality of life — and warrants specialist-level management.
Symptoms and triggers
Moderate to severe unilateral, pulsating headache lasting 4–72 hours
Nausea, vomiting, photophobia, phonophobia
Aura in some individuals: visual, sensory, or speech disturbances
Genetic contribution: family history increases likelihood, particularly for migraine with aura
Treatment landscape
Managing migraine: from first-line to emerging options
Treatment is individualised following clinical assessment and focuses on reducing frequency, severity, and functional impact. The approach typically combines acute treatment (managing individual attacks) with preventive treatment (reducing attack frequency).
01
Acute treatments
Over-the-counter analgesics for mild episodes; triptans (e.g., sumatriptan) for moderate to severe attacks; anti-nausea medications where needed. Acute treatment taken too frequently can lead to medication overuse headache — this requires specific management.
02
Preventive medications
Beta-blockers (e.g., propranolol), certain antidepressants (e.g., amitriptyline), anticonvulsants (e.g., topiramate), and CGRP inhibitors (e.g., erenumab) — the most targeted class available, acting on the migraine-specific pathway. Selection depends on individual history, comorbidities, and tolerability.
03
Psychological and physical therapies
CBT for stress-related contributors and pain management. Physiotherapy where cervicogenic or postural factors contribute. Biofeedback for physiological stress awareness. These are clinically meaningful components of a comprehensive plan, not adjuncts.
04
rTMS — investigational
For patients with inadequate response to standard preventive treatments, rTMS targeting brain regions involved in migraine pathways is under investigation. Some protocols show reductions in monthly migraine days. Offered at Brain Aid Clinics off-label under psychiatrist oversight. Not Medicare-funded for migraine in Australia.
Investigational neuromodulation
rTMS for migraine
Repetitive TMS has been investigated as a non-invasive, drug-free approach targeting the cortical and trigeminovascular circuits involved in migraine pathophysiology. Evidence from clinical studies — including systematic reviews through 2025 — shows variable outcomes, with some protocols demonstrating reductions in monthly migraine frequency in patients with chronic or refractory migraine.
Single-pulse TMS devices are FDA-cleared in the United States for acute and preventive migraine treatment. In Australia, rTMS for migraine is not TGA-approved and is not Medicare-funded as a standalone indication. It is considered at Brain Aid Clinics in specialist consultation for patients who have not achieved adequate relief from standard treatments.
At Brain Aid Clinics, MRI-guided neuronavigation ensures stimulation reaches the intended cortical target based on your individual brain anatomy — not a population-average estimate. Individual responses vary; realistic expectations are discussed thoroughly before treatment commences.
When rTMS may be considered
Inadequate response to preventive medication
Where two or more preventive treatments have been tried without sufficient reduction in migraine frequency.
Medication intolerance
Where side effects from preventive or acute medications make sustained pharmacological treatment impractical.
Comorbid treatment-resistant depression
Where migraine coexists with depression that has not responded to medication — Medicare rebates may apply to the depression component.
Preference for non-pharmacological approach
For patients seeking an evidence-informed, drug-free option within a comprehensive management plan.
Migraine involves complex changes in brain signalling, neurotransmitter activity, and trigeminovascular function. The exact mechanisms are not fully understood, but genetic factors play a significant role — family history increases likelihood, particularly for migraine with aura. Environmental and lifestyle triggers (hormonal changes, stress, sleep disruption, dietary factors, bright lights, strong smells) can precipitate individual attacks in predisposed individuals. Tracking personal triggers supports more effective management.
How is migraine diagnosed?
Diagnosis is clinical — made by a GP or neurologist based on symptom history, medical background, and neurological assessment. No single diagnostic test exists for migraine. Imaging or blood tests may be used to exclude other causes where symptoms are atypical or a new or progressive headache pattern has developed.
Can migraines be cured?
There is currently no cure for migraine. Management focuses on reducing attack frequency, shortening duration, and minimising functional impact. With appropriate preventive treatment, many patients achieve significant improvement. Some experience a natural reduction in frequency over time, particularly after midlife. Individualised, consistent management produces the best outcomes.
When should I see a doctor about my migraines? +
Seek assessment if migraines occur frequently (more than 4–5 days per month), significantly affect daily life, fail to respond to over-the-counter treatments, or are accompanied by new or atypical symptoms such as sudden severe onset, vision loss, weakness, confusion, or fever. Following a head injury, any new headache warrants urgent review. Seek immediate medical attention for any sudden, severe headache that feels different from previous migraines.
Is rTMS covered by Medicare for migraine?
No — Medicare rebates for rTMS are currently limited to treatment-resistant depression in Australia. rTMS for migraine is not Medicare-funded as a standalone indication. Where migraine coexists with treatment-resistant depression, Medicare rebates (MBS 14216 and 14217) may apply to the depression component of treatment. Our team can advise on your specific circumstances at assessment.
Where can I find additional support for migraine management?
Migraine & Headache Australia (migraine.org.au) provides condition-specific resources and peer support. Healthdirect Australia (healthdirect.gov.au) offers general health information. Your GP can refer to a neurologist or headache specialist for complex presentations. Pain Australia (painaustralia.org.au) provides resources for chronic pain including headache disorders. If you are experiencing mental health difficulties alongside your migraine condition, Lifeline (13 11 14) and Beyond Blue (1300 22 4636) offer support.
Clinical and regulatory note: rTMS for migraine is investigational in Australia and is not TGA-approved or Medicare-funded for this indication. It is offered at Brain Aid Clinics off-label under psychiatrist oversight with full informed consent. All information is for general informational purposes and does not constitute medical advice. Please consult a qualified health professional. Brain Aid Clinics operates within AHPRA-compliant clinical and regulatory boundaries. ABN 76 664 676 420.
Get in touch with us.
Fill in the form and we’ll be in contact within 24–48 business hours.
K
Who are you?
We’d love to know how to reach you.
A
What brings you here?
Helps us prepare before your first contact.
R
Your goals
In your own words — no right answers.
E
Medicare details
Optional — only if you plan to use Medicare.
Complete below only if applicable. Our team will assist with eligibility at consultation.
We’ll be in touch within 24–48 business hours. One of our team will reach out personally — no obligation, no pressure.
Your information is kept strictly confidential. By submitting you agree to our Privacy Policy.
